Literature DB >> 11122883

Isolated limb perfusion for extremity sarcoma.

B W Feig1.   

Abstract

Isolated limb perfusion has been used in patients with extremity sarcomas for over 40 years. In the majority of patients this approach has been employed as a limb-sparing alternative for patients with amputation as their only treatment option. Despite this long history of use in the treatment of patients with extremity sarcomas, many questions remain with respect to the appropriate drug or combination of drugs to be used in the perfusion circuit, the role of hyperthermia in isolated perfusion, and the use of hyperthermic perfusion in the neoadjuvant or adjuvant setting. Although many non-randomized studies have been performed, they suffer from a variety of problems, including small patient numbers, variety of chemotherapeutic agents employed, multiple levels of hyperthermia, and subjective evaluation of what constitutes amputation as a potential treatment option.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122883     DOI: 10.1007/s11912-000-0101-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  15 in total

1.  Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit.

Authors:  O CREECH; E T KREMENTZ; R F RYAN; J N WINBLAD
Journal:  Ann Surg       Date:  1958-10       Impact factor: 12.969

2.  Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities.

Authors:  H J Hoekstra; H Schraffordt Koops; W M Molenaar; J Oldhoff
Journal:  Cancer       Date:  1987-10-15       Impact factor: 6.860

3.  Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities.

Authors:  R F Pommier; H S Moseley; J Cohen; C S Huang; R Townsend; W S Fletcher
Journal:  Am J Surg       Date:  1988-05       Impact factor: 2.565

4.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

Authors:  D Lienard; P Ewalenko; J J Delmotte; N Renard; F J Lejeune
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

5.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

Authors:  A M Eggermont; H Schraffordt Koops; J M Klausner; B B Kroon; P M Schlag; D Liénard; A N van Geel; H J Hoekstra; I Meller; O E Nieweg; C Kettelhack; G Ben-Ari; J C Pector; F J Lejeune
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

6.  An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.

Authors:  K Antman; J Crowley; S P Balcerzak; S E Rivkin; G R Weiss; A Elias; R B Natale; R M Cooper; B Barlogie; D L Trump
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

7.  Soft tissue sarcomas of the extremity. Multidisciplinary therapy employing hyperthermic perfusion.

Authors:  J S Stehlin; P D de Ipolyi; B C Giovanella; A E Gutierrez; R F Anderson
Journal:  Am J Surg       Date:  1975-12       Impact factor: 2.565

8.  Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas.

Authors:  C R Rossi; A Vecchiato; M Foletto; D Nitti; V Ninfo; A Fornasiero; G Sotti; A Tregnaghi; P Melanotte; M Lise
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

9.  Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities.

Authors:  J M Klaase; B B Kroon; C Benckhuijsen; A N van Geel; C E Albus-Lutter; J Wieberdink
Journal:  Cancer       Date:  1989-08-01       Impact factor: 6.860

10.  Chemotherapy of sarcomas of the limbs by regional perfusion.

Authors:  E T Krementz; R D Carter; C M Sutherland; I Hutton
Journal:  Ann Surg       Date:  1977-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.